Procurement
Expert Panel
Create New Account
Login
logo
Report store
Insights
Survey
Consulting
Book discovery call
logo

Oncology Therapeutics Market: Current Analysis and Forecast (2021-2027)

Region:Global

Product Code:UMHE21248

Download Sample Report
Published On

June 2021

Total pages

194

About the Report

ONCOLOGY THERAPEUTICS ARE MAINLY USED FOR THE TREATMENT OF CANCER THROUGH SURGERY, CHEMOTHERAPY, RADIOTHERAPY, OR TARGETED THERAPY. THOUGH THERE ARE MANY KINDS OF CANCER, ONLY A FEW DOMINATES AMONG THE POPULATION. MORE THAN A MILLION CANCER CASES ARE DIAGNOSED EVERY YEAR AND AS PER THE AMERICAN CANCER SOCIETY (2021), 1 IN 3 PEOPLE WILL BE DIAGNOSED WITH CANCER IN THEIR LIFETIME. THE DEMAND FOR ONCOLOGY THERAPEUTICS IS INCREASING ON ACCOUNT OF INCREASING CANCER PREVALENCE, GROWING GERIATRIC POPULATION, RISE IN R&D INITIATIVES AND PRIVATE AS WELL AS PUBLIC FUNDING, AND GOVERNMENTS PATIENT ASSISTANCE PROGRAMS. MOREOVER, THE UPSURGE IN THE COLLABORATIONS BETWEEN PHARMACEUTICAL COMPANIES ALSO PROPELS THE MARKET GROWTH. FOR INSTANCE, MERCK SHARP & DOHME (MSD) HAVE ANNOUNCED THEIR RESEARCH COLLABORATION WITH TAIHO PHARMACEUTICAL AND ASTEX PHARMACEUTICALS FOR THE DEVELOPMENT OF SMALL-MOLECULE INHIBITORS AGAINST SEVERAL DRUG TARGETS. HOWEVER, SOME OF THE RESTRAINTS IN THE MARKET INCLUDE THE HIGH COST AND THE ADVERSE EFFECTS ASSOCIATED WITH THE USE OF ONCOLOGY THERAPEUTICS. FOR INSTANCE, THE SECOND TOP-SELLING DRUG HERCEPTIN 440 MG INJ. DEVELOPED BY ROCHE FOR THE TREATMENT OF BREAST CANCER COSTS AROUND USD 1,823.8 AND THE LONG-TERM USE OF THIS DRUG CAN LEAD TO CONGESTIVE HEART FAILURE.

BASED ON THERAPY TYPE, THE MARKET IS FRAGMENTED INTO CHEMOTHERAPY, TARGETED THERAPY, IMMUNOTHERAPY, AND HORMONAL THERAPY. THE MAIN PROBLEM, PARTICULARLY IN CANCER THERAPY IS THE DAMAGING OF NORMAL TISSUE DUE TO THE HIGH DOSE OF CHEMOTHERAPEUTICS. THE MAIN AIM OF TARGETED THERAPY IS TO CONCENTRATE THE DRUG AT THE TARGETED SITE THROUGH PASSIVE OR ACTIVE TARGETING SO THAT ONLY A SMALL AMOUNT OF DRUG MOLECULES CAN DAMAGE THE NORMAL TISSUE. THE TARGETED THERAPY SEGMENT IS EXPECTED TO SHOW THE FASTEST GROWTH IN THE UPCOMING YEARS, OWING TO REDUCED TOXICITY, ENHANCED STABILITY OF THE DRUG, AND POTENTIAL TO DELIVER MULTIPLE DRUGS AT THE TARGETED SITE. THE TARGETED THERAPY INCLUDES APOPTOSIS INDUCERS, ANGIOGENESIS INHIBITORS, GENE EXPRESSION MODULATORS, HORMONE THERAPIES, IMMUNOTHERAPIES, AND SIGNAL TRANSDUCTION INHIBITORS. FOR INSTANCE, SMALL INTERFERING (SIRNA) BASED TARGETED DRUG DELIVERY SYSTEM IS WIDELY USED FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC), AND AS PER THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, NSCLC IS THE MOST COMMON TYPE OF LUNG CANCER WHICH ACCOUNTS FOR THE 84% OF ALL THE LUNG CANCER DIAGNOSIS IN THE US.

BASED ON CANCER TYPE, THE MARKET IS FRAGMENTED INTO BLOOD CANCER, LUNG CANCER, COLORECTAL CANCER, PROSTATE CANCER, BREAST CANCER, CERVICAL CANCER, AND OTHERS. LUNG CANCER IS EXPECTED TO RECORD THE HIGHEST GROWTH IN THE UPCOMING YEARS OWING TO ITS HIGH PREVALENCE IN BOTH THE DEVELOPED AS WELL AS DEVELOPING COUNTRIES. ACCORDING TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, LUNG CANCER IS THE SECOND MOST COMMON CANCER AND APPROXIMATELY 235,760 ADULTS (119,100 MEN AND 116,660 WOMEN) IN THE US WILL BE DIAGNOSED WITH LUNG CANCER BY THE END OF 2021. BASED ON THE ROUTE OF ADMINISTRATION, THE MARKET IS FRAGMENTED INTO ORAL, PARENTERAL, AND OTHERS. THE PARENTERAL SEGMENT IS EXPECTED TO RECORD THE HIGHEST GROWTH IN THE UPCOMING YEARS OWING TO BYPASSING OF FIRST-PASS METABOLISM, QUICK ACTION, AND HIGH EFFICACY. MOREOVER, THE RISE IN FDA APPROVALS IN THE PAST FEW YEARS FOR CANCER CHEMOTHERAPEUTICS ALSO PROPELS THE MARKET GROWTH. FOR INSTANCE, FDA APPROVED GSK'S BLENREP ANTI-BCMA (B-CELL MATURATION ANTIGEN) INJECTION IN 2021 AS A MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.

BASED ON END-USER, THE MARKET IS FRAGMENTED INTO HOSPITALS, SPECIALTY CLINICS, CANCER AND RADIATION THERAPY CENTERS. CANCER AND RADIATION THERAPY CENTERS ARE EXPECTED TO DOMINATE THE MARKET IN THE UPCOMING YEARS OWING TO THE LARGE NUMBER OF CANCER TREATMENTS TAKING PLACE AT SUCH CENTERS ACROSS THE GLOBE. FOR INSTANCE, THE HOSPITAL OF THE UNIVERSITY OF PA, ABRAMSON CANCER CENTER, UNITED STATES IS THE BEST CANCER CENTER, WITH MAJOR FOCUS ON INNOVATION, TRANSLATIONAL MEDICINE, AND CUTTING-EDGE TECHNOLOGY. IT CONSISTS OF A CANCER RISK EVALUATION PROGRAM, BONE MARROW AND STEM CELL TRANSPLANT PROGRAM, GI CANCER PROGRAM, HIV ONCOLOGY PROGRAM GENITOURINARY CANCER PROGRAM, PROTON THERAPY, MELANOMA, AND PIGMENTED LESION PROGRAM, AND TELEGENICS PROGRAM.

FOR A BETTER UNDERSTANDING OF THE MARKET AND ADOPTION OF THE PROCEDURE, THE REPORT PROVIDES DETAILED ANALYSIS FOR MAJOR REGIONS INCLUDING NORTH AMERICA (US, CANADA, AND THE REST OF NORTH AMERICA), EUROPE (GERMANY, FRANCE, ITALY, SPAIN, UK, AND REST OF EUROPE), ASIA-PACIFIC (CHINA, JAPAN, INDIA, AUSTRALIA, AND REST OF APAC), AND REST OF WORLD. NORTH AMERICA DOMINATES THE ONCOLOGY THERAPEUTICS MARKET ON ACCOUNT OF THE INCREASING PREVALENCE OF CANCER CASES AND GROWING INVESTMENT ON R&D BY PHARMA COMPANIES. AS PER BREAST CANCER.ORG, IN 2021, APPROXIMATELY 281,550 NEW CASES OF INVASIVE BREAST CANCER ARE EXPECTED TO BE DIAGNOSED IN WOMEN IN THE U.S., ALONG WITH 49,290 NEW CASES OF NON-INVASIVE (IN SITU) BREAST CANCER.

SOME OF THE MAJOR PLAYERS OPERATING IN THE MARKET INCLUDE AMGEN INC., BAYER AG, JOHNSON & JOHNSON SERVICES, INC, MERCK & CO., INC., NOVARTIS AG, PFIZER INC., F. HOFFMANN-LA ROCHE LTD, ASTRAZENECA, BRISTOL-MYERS SQUIBB COMPANY, AND ELI LILLY AND COMPANY. SEVERAL M&AS ALONG WITH PARTNERSHIPS HAVE BEEN UNDERTAKEN BY THESE PLAYERS TO BOOST THEIR PRESENCE IN DIFFERENT REGIONS.

Scope of the Report

Products

Oncology Therapeutics are mainly used for the treatment of cancer through surgery, chemotherapy, radiotherapy, or targeted therapy.

Companies

AMGEN INC.

BAYER AG

JOHNSON & JOHNSON SERVICES

INC

MERCK & CO.

INC.

NOVARTIS AG

PFIZER INC.

F. HOFFMANN-LA ROCHE LTD

ASTRAZENECA

BRISTOL-MYERS SQUIBB COMPANY

AND ELI LILLY AND COMPANY

Table of Contents

1 MARKET INTRODUCTION

1.1 MARKET DEFINITIONS

1.2 LIMITATIONS

1.3 STAKE HOLDERS

1.4 CURRENCY USED IN REPORT

2 RESEARCH PROCESS & RESEARCH METHODOLOGY

2.1 RESEARCH METHODOLOGY OF THE ONCOLOGY THERAPEUTICS MARKET

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL ONCOLOGY THERAPEUTICS MARKET ANALYSIS 2019-27F

6 MARKET INSIGHTS BY THERAPY TYPE

6.1 CHEMOTHERAPY

6.2 TARGETED THERAPY

6.3 IMMUNOTHERAPY

6.4 HORMONAL THERAPY

7 MARKET INSIGHTS BY CANCER TYPE

7.1 BLOOD CANCER

7.2 LUNG CANCER

7.3 COLORECTAL CANCER

7.4 PROSTATE CANCER

7.5 BREAST CANCER

7.6 CERVICAL CANCER

7.7 OTHERS

8 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

8.1 ORAL

8.2 PARENTERAL

8.3 OTHERS

9 MARKET INSIGHTS BY END-USER

9.1 HOSPITALS

9.2 SPECIALTY CLINICS

9.3 CANCER AND RADIATION THERAPY CENTERS

9.4 OTHER ED-USERS

10 MARKET INSIGHTS BY REGION

10.1 NORTH AMERICA ONCOLOGY THERAPEUTICS MARKET

10.1.1 UNITED STATES

10.1.2 CANADA

10.1.3 REST OF NORTH AMERICA

10.2 EUROPE ONCOLOGY THERAPEUTICS MARKET

10.2.1 GERMANY

10.2.2 FRANCE

10.2.3 UNITED KINGDOM

10.2.4 ITALY

10.2.5 SPAIN

10.2.6 REST OF EUROPE

10.3 ASIA PACIFIC ONCOLOGY THERAPEUTICS MARKET

10.3.1 CHINA

10.3.2 JAPAN

10.3.3 INDIA

10.3.4 AUSTRALIA

10.3.5 REST OF ASIA PACIFIC

10.4 REST OF WORLD ONCOLOGY THERAPEUTICS MARKET

11 DEMAND AND SUPPLY SIDE ANALYSIS

11.1 DEMAND SIDE ANALYSIS

11.2 SUPPLY SIDE ANALYSIS

11.2.1 TOP PRODUCT LAUNCHES

11.2.2 TOP BUSINESS PARTNERSHIPS

11.2.3 TOP BUSINESS EXPANSIONS, INVESTMENTS, AND DIVESTITURES

11.2.4 TOP MERGER AND ACQUISITIONS

12 VALUE CHAIN ANALYSIS

13 GLOBAL ONCOLOGY THERAPEUTICS MARKET TRENDS & INSIGHTS

14 GLOBAL ONCOLOGY THERAPEUTICS MARKET DYNAMICS

14.1 DRIVERS

14.2 CHALLENGES

14.3 IMPACT ANALYSIS

15 GLOBAL ONCOLOGY THERAPEUTICS MARKET OPPORTUNITIES

16 COMPETITIVE SCENARIO

17 COMPANY PROFILED

17.1 AMGEN INC.

17.2 BAYER AG

17.3 JOHNSON & JOHNSON SERVICES, INC.

17.4 NOVARTIS AG

17.5 PFIZER INC.

17.6 F HOFFMANN-LA ROCHE LTD

17.7 ASTRAZENECA

17.8 BRISTOL-MYERS SQUIBB COMPANY

17.10 ELI LILLY AND COMPANY

18 DISCLAIMER

Research Methodology

Why Buy From Us?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022